Table 1.

Baseline characteristics of the study participants

No.	Gender	Age	Myeloma isotype	Vaccination dose level
1	M	62	λ-light chain	0.25 mg
2	M	58	IgA1-κ/light chain	0.25 mg
3	M	56	IgG1-λ	0.25 mg
4	F	69	IgG1-λ	0.25 mg
5	F	59	IgG1-λ	0.25 mg
6	F	62	IgG1-κ	1.25 mg
7	F	50	IgG1-κ	1.25 mg
8	M	59	IgG1-κ	1.25 mg
9	M	57	IgG1-κ	1.25 mg
10	M	63	IgG1-λ	1.25 mg
11	M	52	IgG1-κ	2.5 mg
12	M	62	κ-light chain	2.5 mg
13	M	63	IgG1-κ	2.5 mg
14	F	60	IgG1-κ	2.5 mg
15	M	66	IgG1-κ	2.5 mg